# A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)

> **NCT01686620** · PHASE2 · COMPLETED · sponsor: **Biodel** · enrollment: 132 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** BIOD-123
- **DRUG:** Lispro (Humalog)

## Key facts

- **NCT ID:** NCT01686620
- **Lead sponsor:** Biodel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686620, "A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01686620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*